Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
For solid tumors, however, the efficacy of CAR T-cell treatments has been limited and progress “more incremental,” Christian Hinrichs, MD, with Rutgers Cancer Institute in New Brunswick ...
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...
IHC: Immunohistochemistry; NSCLC: Non-small-cell lung cancer. Adapted with permission from [77]. The authors have no relevant affiliations or financial involvement with any organization or entity ...
Mobily 9M 2024 profit up 43% to SAR 2.12B; Q3 at SAR 828.6M 9 M 2024 Mobily H1 2024 profit up 35% to SAR 1.29B, Q2 at SAR 661M 6 M 2024 Mobily Q1 2024 profit leaps 37% to SAR 638M 3 M 2024 Mobily 2023 ...
The tumor tissue within the thyroid exhibited immature cells with a high nuclear-cytoplasmic ratio, forming daisy-shaped cluster structures, large nuclei with coarse chromatin, and frequent apoptosis ...
Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol; Department of Oncology, 1st Faculty of Medicine, Charles University and ...
The Maastricht MultiModal Molecular Imaging (M4I) institute, Division of Imaging Mass Spectrometry (IMS), Maastricht University, 6229 ER Maastricht, The Netherlands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback